{"filing":{"accession_number":"0001193125-26-323753","cik":"0001478320","ticker":"ADPT","company_name":"Adaptive Biotechnologies Corp","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-24","primary_document":"adpt-20260724.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm"},"events":[{"id":21660,"run_id":19540,"accession_number":"0001193125-26-323753","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Adaptive Biotechnologies disclosed Q2 2026 financial results (quarter ended June 30, 2026) via press release, reporting revenue of $71.6 million, net loss of $39.9 million, and updated full-year MRD revenue guidance to $268–$278 million, with clonoSEQ test volume growth of 43%.","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21354,"accession_number":"0001193125-26-323753","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Adaptive Biotechnologies' financial results for Q2 2026 (quarter ended June 30, 2026), filed on July 29, 2026 via Item 2.02. The press release (Exhibit 99.1) reports revenue of $71.6 million, net loss of $39.9 million, and updated full-year MRD revenue guidance to $268-$278 million. The disclosure includes detailed financial statements and operational metrics (e.g., clonoSEQ test volume growth of 43%), making it a material earnings announcement typical of Item 2.02 filings.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:21:46.348614+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":21661,"run_id":19540,"accession_number":"0001193125-26-323753","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. Harlan Robins, Chief Scientific Officer and Co-founder, transitioned out of his executive officer role into a strategic consultant position, representing a material change in executive leadership.","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21355,"accession_number":"0001193125-26-323753","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Harlan Robins, Chief Scientific Officer and Co-founder, is transitioning out of his executive officer role into a strategic consultant position. While the filing frames this as a \"transition\" rather than a departure, the substance is that he is leaving his officer position. The supplemental earnings release confirms \"Harlan Robins is transitioning roles at Adaptive from Chief Scientific Officer to a strategic consultant,\" indicating a material change in executive leadership. The absence of any disagreement or performance issues does not negate the materiality of a co-founder and CSO stepping down from executive duties.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:21:46.348614+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21354,"accession_number":"0001193125-26-323753","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Adaptive Biotechnologies' financial results for Q2 2026 (quarter ended June 30, 2026), filed on July 29, 2026 via Item 2.02. The press release (Exhibit 99.1) reports revenue of $71.6 million, net loss of $39.9 million, and updated full-year MRD revenue guidance to $268-$278 million. The disclosure includes detailed financial statements and operational metrics (e.g., clonoSEQ test volume growth of 43%), making it a material earnings announcement typical of Item 2.02 filings.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:21:46.348614+00:00","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-07-29"},{"id":21355,"accession_number":"0001193125-26-323753","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Harlan Robins, Chief Scientific Officer and Co-founder, is transitioning out of his executive officer role into a strategic consultant position. While the filing frames this as a \"transition\" rather than a departure, the substance is that he is leaving his officer position. The supplemental earnings release confirms \"Harlan Robins is transitioning roles at Adaptive from Chief Scientific Officer to a strategic consultant,\" indicating a material change in executive leadership. The absence of any disagreement or performance issues does not negate the materiality of a co-founder and CSO stepping down from executive duties.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:21:46.348614+00:00","company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","filing_date":"2026-07-29"}]}